Ashland Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.8B-12.8% YoYTTM through 30 Jun 2026
Net Income $52M-69.2% YoYTTM through 30 Jun 2026
Free Cash Flow $250MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 30.5% |
| EBITDA Margin | 17.8% |
| Operating Margin | 8.1% |
| Net Margin | 2.8% |
Returns
2.8%ROE
1.1%ROA
1.9%ROIC
Balance Sheet Health
Debt / Equity0.73x
Current Ratio3.05x
Net Debt$934M
Cash & Equivalents$440M
Quality Metrics
Altman Z-Score2.14
Piotroski F-Score6 / 9
FCF Margin13.6%
Rule of 4014.8
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $1.8B
Diluted EPS$1.05TTMFY2019: $8.15
Dividend
$0.84Per share, FY20261.20%Yield-6.6%5-yr growth
Capital Allocation
R&D Spend$54M
Capex Intensity4.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Life Sciences | View detailsLife Sciences remains a core resilient segment focused on high-margin pharmaceutical and personal care applications. | ||
| Personal Care | View detailsPersonal Care continues to show resilient demand, particularly in biofunctional actives, skin care, and hair care. | ||
| Specialty Additives | View detailsSpecialty Additives continues to face pricing and cost headwinds, reflecting sluggish core demand in architectural coatings. | ||
| Intermediates | View detailsIntermediates continues to manage through cyclical trough-like conditions in the BDO market. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.